8.10 0.00 (0.00%)
After hours: 5:22PM EDT
|Bid||7.70 x 900|
|Ask||8.11 x 1000|
|Day's Range||7.68 - 8.49|
|52 Week Range||5.20 - 12.31|
|Beta (3Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.88|
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “We successfully executed a number of strategic initiatives to advance our mission, and with the recent completion of our merger with Keryx, we have emerged as a leading, fully-integrated renal company with the potential to greatly improve care for patients with kidney disease. Mr. Butler continued, “With respect to vadadustat, our lead product candidate, we believe that it has the potential to set a new standard of care for patients with anemia due to chronic kidney disease with a differentiated clinical profile.
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Growth trendsIn its fourth-quarter earnings investor presentation, MannKind Corporation (MNKD) announced that Afrezza had seen fiscal 2018 net sales of $17.3
MannKind or Akebia: Which Is a Better Biotech Pick This Month?Share price movementsOn March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 11) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
– Each Study Met Its Primary Endpoint –
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced it will host a fourth quarter and full-year 2018 investor update conference call and webcast at 4:30 p.m. Eastern Time on Monday, March 18, 2019. Individuals interested in participating in the call should dial (877) 458-0977 (U.S. and Canada) or (484) 653-6724 (international) using conference ID number 1376157. Beginning the morning of March 19, 2019, the call will be available for replay via telephone and the archived webcast will be available on Akebia’s website.
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 32,800 shares of Akebia’s common stock on February 28, 2019, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $7.28 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Today I will be providing a simple run through ofRead More...
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
John Butler became the CEO of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 9:30 a.m. Pacific Time at the Westin St. Francis in San Francisco. A live webcast of the presentation will be available on the company’s website at www.akebia.com. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease.
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]
Legendary investor Seth Klarman (Trades, Portfolio) disclosed Thursday that his long-term stake in kidney care company Keryx Biopharmaceuticals (KERX) closed as it converted into a stake in Akebia Therapeutics (AKBA) upon the merger of the two companies. Warning! GuruFocus has detected 2 Warning Signs with TBPH.
An intriguing billionaire, David Abrams launched his own investment firm Abrams Capital Management back in 1999 in Boston, and he has run it very successfully so far. When we say intriguing, we refer to David Abrams’ low profile and interesting investment strategy. Let’s start from the beginning – David Abrams graduated from the University of Pennsylvania […]
Akebia Therapeutics Inc (NASDAQ: AKBA ) announced shareholder approval this week for its merger with Keryx Biopharmaceuticals (NASDAQ: KERX ). The Analyst Analyst Reni Benjamin of Raymond James maintains ...